Vor
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
500 Boylston St Fl 13, Boston, Massachus...Phone Number
(617) 655-6580Website
www.vorbio.comRevenue
-Stock Symbol
VORIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
3
4
1
1
1
About Vor
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide.Explore more
Vor Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vor your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Vor, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Vor has recently received funding, and reach out quickly before it becomes old news!
Check out if Vor is spiking on competitors!
Product Launch: Get notified when Vor launches new products
Funding: Get notified immidiatlly once Vor has new funding data
Click to see if Vor had a recent Job posting/layoffs
Earning: See what the market has to say on Vor recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Vor
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Vor
Compare insights from companies similar to Vor, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vor is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vor is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vor.
Vor financials insights
Gather financial insights about Vor, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$42M
2020
Series B
$110M
2024
Private Equity
$55.6M
2025
Stock/Share Issuance
$175M
Vor Tech Stack
A closer look at the technologies used by Vor
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
New Hire
Executive Move
Jeremy Sokolove has joined the organization as Chief Medical Officer. Previously Sokolove served as Chief Medical Officer, In-Residence for Roivant Sciences.
Executive Moves, New Hire
Hiring Plans
Vor has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
New Hire
Executive Move
Executive Moves, New Hire
Vor News & Media
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 15,150 shares of Vor Bio’s common stock to 7 newly hiredTelitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
First regulatory approval for Sjögren’s disease (SjD)Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Vor
Sign Up For FreeTo access detailed company insights
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide.... Read More
